Autopsy report · NCT03692338

INTERVAL: Ipilimumab and Nivolumab Combination Therapy: A Study of a Supervised or Semi-Supervised Exercise InteRVention or Usual Care With Functional Capacity and Quality of Life Evaluations in Subjects With Advanced or Metastatic RenAL Cell Carcinoma

Cause of deathSlow enrollment Automatic label, confidence 0.9, unverified. How labels are made.

“Poor accrual”

The sponsor’s own words in the registry.

Life of this trial

Registered 2 months before it started.
Ran for about 1 year 1 month before it stopped.
2 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Na
Sponsor: Duke University
Sponsor type: University, hospital or other
Conditions: Metastatic Renal Cell Carcinoma
Interventions: Exercise
Participants: 2
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.